Cargando…
The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy
PURPOSE: To investigate the diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET), as an imaging biomarker, for predicting pathological response and prognosis of unresectable hepatocellular carcinoma (HCC) patients treated with Lenvatinib and programmed cell death...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196479/ https://www.ncbi.nlm.nih.gov/pubmed/37215117 http://dx.doi.org/10.3389/fimmu.2023.1151967 |
_version_ | 1785044364143099904 |
---|---|
author | Wang, Guanyun Zhang, Wenwen Luan, Xiaohui Wang, Zhanbo Liu, Jiajin Xu, Xiaodan Zhang, Jinming Xu, Baixuan Lu, Shichun Wang, Ruimin Ma, Guangyu |
author_facet | Wang, Guanyun Zhang, Wenwen Luan, Xiaohui Wang, Zhanbo Liu, Jiajin Xu, Xiaodan Zhang, Jinming Xu, Baixuan Lu, Shichun Wang, Ruimin Ma, Guangyu |
author_sort | Wang, Guanyun |
collection | PubMed |
description | PURPOSE: To investigate the diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET), as an imaging biomarker, for predicting pathological response and prognosis of unresectable hepatocellular carcinoma (HCC) patients treated with Lenvatinib and programmed cell death protein 1 (PD-1) inhibitors as a conversion therapy. METHODS: A total of 28 unresectable HCC patients with BCLC stage B or C were treated with Lenvatinib and PD-1 inhibitors before surgery. The (18)F-FDG PET/CT scans were acquired before pre- (scan-1) and post-conversion therapy (scan-2). The maximum standardized uptake value (SUVmax), TLR (tumor-to-normal liver standardized uptake value ratio), and the percentages of post-treatment changes in metabolic parameters (ΔSUVmax [%] and ΔTLR [%]) were calculated. Major pathological response (MPR) was identified based on the residual viable tumor in the resected primary tumor specimen (≤10%). Differences in the progression-free survival (PFS) and overall survival (OS) stratified by ΔTLR were examined by the Kaplan-Meier method. RESULTS: 11 (11/28, 39.3%) patients were considered as MPR responders and 17 (17/28, 60.7%) patients as non-MPR responders after conversion therapy. ΔSUVmax (-70.0 [-78.8, -48.8] vs. -21.7 [-38.8, 5.7], respectively; P<0.001) and ΔTLR (-67.6 [-78.1, -56.8] vs. -18.6 [-27.9, 4.0], respectively; P<0.001) were reduced in the responder group than those in the non-responder group. According to the results of the receiver operating characteristic curve analysis, ΔTLR showed an excellent predictive value for the MPR of primary HCC lesions (area under curve=0.989, with the optimal diagnostic threshold of -46.15). When using ΔTLR of -21.36% as a threshold, patients with ΔTLR-based metabolic response had superior PFS (log-rank test, P=0.001) and OS (log-rank test, P=0.016) compared with those without ΔTLR-based metabolic response. CONCLUSION: (18)F-FDG PET is a valuable tool for predicting pathological response and prognosis of unresectable HCC patients treated by Lenvatinib combined with PD-1 as a conversion therapy. |
format | Online Article Text |
id | pubmed-10196479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101964792023-05-20 The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy Wang, Guanyun Zhang, Wenwen Luan, Xiaohui Wang, Zhanbo Liu, Jiajin Xu, Xiaodan Zhang, Jinming Xu, Baixuan Lu, Shichun Wang, Ruimin Ma, Guangyu Front Immunol Immunology PURPOSE: To investigate the diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET), as an imaging biomarker, for predicting pathological response and prognosis of unresectable hepatocellular carcinoma (HCC) patients treated with Lenvatinib and programmed cell death protein 1 (PD-1) inhibitors as a conversion therapy. METHODS: A total of 28 unresectable HCC patients with BCLC stage B or C were treated with Lenvatinib and PD-1 inhibitors before surgery. The (18)F-FDG PET/CT scans were acquired before pre- (scan-1) and post-conversion therapy (scan-2). The maximum standardized uptake value (SUVmax), TLR (tumor-to-normal liver standardized uptake value ratio), and the percentages of post-treatment changes in metabolic parameters (ΔSUVmax [%] and ΔTLR [%]) were calculated. Major pathological response (MPR) was identified based on the residual viable tumor in the resected primary tumor specimen (≤10%). Differences in the progression-free survival (PFS) and overall survival (OS) stratified by ΔTLR were examined by the Kaplan-Meier method. RESULTS: 11 (11/28, 39.3%) patients were considered as MPR responders and 17 (17/28, 60.7%) patients as non-MPR responders after conversion therapy. ΔSUVmax (-70.0 [-78.8, -48.8] vs. -21.7 [-38.8, 5.7], respectively; P<0.001) and ΔTLR (-67.6 [-78.1, -56.8] vs. -18.6 [-27.9, 4.0], respectively; P<0.001) were reduced in the responder group than those in the non-responder group. According to the results of the receiver operating characteristic curve analysis, ΔTLR showed an excellent predictive value for the MPR of primary HCC lesions (area under curve=0.989, with the optimal diagnostic threshold of -46.15). When using ΔTLR of -21.36% as a threshold, patients with ΔTLR-based metabolic response had superior PFS (log-rank test, P=0.001) and OS (log-rank test, P=0.016) compared with those without ΔTLR-based metabolic response. CONCLUSION: (18)F-FDG PET is a valuable tool for predicting pathological response and prognosis of unresectable HCC patients treated by Lenvatinib combined with PD-1 as a conversion therapy. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196479/ /pubmed/37215117 http://dx.doi.org/10.3389/fimmu.2023.1151967 Text en Copyright © 2023 Wang, Zhang, Luan, Wang, Liu, Xu, Zhang, Xu, Lu, Wang and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Guanyun Zhang, Wenwen Luan, Xiaohui Wang, Zhanbo Liu, Jiajin Xu, Xiaodan Zhang, Jinming Xu, Baixuan Lu, Shichun Wang, Ruimin Ma, Guangyu The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title | The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title_full | The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title_fullStr | The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title_full_unstemmed | The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title_short | The role of (18)F−FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy |
title_sort | role of (18)f−fdg pet in predicting the pathological response and prognosis to unresectable hcc patients treated with lenvatinib and pd-1 inhibitors as a conversion therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196479/ https://www.ncbi.nlm.nih.gov/pubmed/37215117 http://dx.doi.org/10.3389/fimmu.2023.1151967 |
work_keys_str_mv | AT wangguanyun theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT zhangwenwen theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT luanxiaohui theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT wangzhanbo theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT liujiajin theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT xuxiaodan theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT zhangjinming theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT xubaixuan theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT lushichun theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT wangruimin theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT maguangyu theroleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT wangguanyun roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT zhangwenwen roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT luanxiaohui roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT wangzhanbo roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT liujiajin roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT xuxiaodan roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT zhangjinming roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT xubaixuan roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT lushichun roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT wangruimin roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy AT maguangyu roleof18ffdgpetinpredictingthepathologicalresponseandprognosistounresectablehccpatientstreatedwithlenvatinibandpd1inhibitorsasaconversiontherapy |